EXPERIMENTAL CLINICAL STUDY OF ENTEROSGEL (METHYLSILICIC ACID HYDROGEL) APPLICATION IN ONCOLOGY PATIENTS DURING THE COURSES OF GAMMA TELETHERAPY AND CHEMORADIOTHERAPY, 2001
Yu.N. Shevchenko, Yu.A. Serezhko
1. During EBRT, all patients have experienced an increase of endogenous intoxication, which can be an indicator of the level of medium-weight molecules. However, in patients treated with Enterosgel, medium-weight molecules level was lower than in the control group and did not rise above 0.300 relative units of extinction.
2. It has been proved that the method of intestinal drug absorption Enterosgel reduced antigen load.
3. Analysis of the results shows feasibility of increasing the daily dose of Enterosgel by 2 times at CRTx. Especially the dose should be increased in the first 15 days of treatment, when the negative influence of EBRT is aggravated by chemotherapy.
4. Application of intestinal adsorbent Enterosgel during EBRT significantly reduces clinical manifestations of radioepithelitis. Improvement of the general condition of all 10 patients allowed to conduct a full treatment course without interruption.